Revelation Biosciences, Inc. announced its financial results for the three months ended March 31, 2025. The company reported a net loss of $2.1 million for the quarter, an improvement from the $2.7 million net loss in Q1 2024. Research and development expenses increased to $858,830 from $717,582 in the prior year, reflecting ongoing clinical study costs.
As of March 31, 2025, Revelation's cash and cash equivalents stood at $3.7 million, a significant decrease from $6.5 million at December 31, 2024. Net cash used in operating activities for the quarter was $2.8 million, consistent with the $2.8 million used in Q1 2024. Based on current projections, the company believes its cash will only fund operations through June 2025.
This limited cash runway raises substantial doubt about the company's ability to continue as a going concern, as explicitly stated in its 10-Q filing. The company plans to seek additional funding through equity or debt financings to address this critical liquidity challenge. CEO James Rolke noted the expanding pipeline and anticipated Phase 1b PRIME clinical study topline data this summer.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.